Role of Cyclin D1 in Breast Carcinoma

Overview

Journal J Res Med Sci

Specialty General Medicine

Date 2014 Feb 14

PMID 24523791

Citations 26

Authors

Fereshteh Mohammadizadeh

Mohsen Hani

Mohammad Ranaee

Marzie Bagheri

Affiliations

Soon will be listed here.

Abstract

Background: Breast carcinoma is the most frequent cancer among women with considerable invasive and metastatic behavior. CCND1, the oncogene encoding cyclin D1, is amplified in a substantial proportion of human cancers. Although cyclin D1 overexpression has been reported in up to 50% of human breast cancers, its prognostic impact on breast carcinoma is still controversial.

Materials And Methods: In this cross-sectional investigation, 89 patients with breast invasive ductal carcinoma enrolled in the study. Tumor tissue samples were stained immunohistochemically for cyclin D1. The marker was semiquantitatively scored using the Allred scoring method and its relationship with ER, PR, and HER2-neu status as well as age, tumor grade and stage was then determined.

Results: Cyclin D1 was strong (S), intermediate (I), weak (W), and negative (N) in 19.1%, 44.9%, 14.6%, and 21.3% of the cases, respectively. Estrogen receptor (ER), progesterone receptor (PR), and HER2- neu were positive in 60.7%, 58.4%, and 36% of the cases, respectively. There was a statistically significant reverse relationship between tumor grade and cyclin D1 (P = 0.009). The relationship between cyclin D1 and both hormone receptors was also statistically significant (P = 0.0001). There was no statistically significant relationship between cyclin D1 on one hand and age, stage, and HER2-neu on the other (P > 0.05).

Conclusion: The reverse relationship between cyclin D1 overexpression and tumor grade as well as its positive relationship with ER and PR in invasive ductal carcinoma suggest that cyclin D1 may directly or indirectly result in maturation and differentiation of tumor cells.

Citing Articles

Expression of Cyclin D1 and Claudin-1 in Invasive Breast Carcinoma and Their Correlation with Clinicopathological Parameters.

Sehrawat R, Dhawan V, Roy M, Kediya A, Nijhawan V Iran J Pathol. 2025; 19(4):408-414.

PMID: 40034931 PMC: 11872039. DOI: 10.30699/ijp.2024.2028643.3299.

Immunohistochemical Expression of Cyclin D1 and p16 in Invasive Breast Carcinoma and Its Association with Clinicopathological Parameters.

Malik S, V S, Ahuja S, Ahluwalia C Indian J Surg Oncol. 2024; 15(4):864-873.

PMID: 39555349 PMC: 11564605. DOI: 10.1007/s13193-024-02015-8.

AFFECT: an R package for accelerated functional failure time model with error-contaminated survival times and applications to gene expression data.

Chen L, Huang H BMC Bioinformatics. 2024; 25(1):265.

PMID: 39138564 PMC: 11323647. DOI: 10.1186/s12859-024-05831-5.

Key target genes related to anti-breast cancer activity of ATRA: A network pharmacology, molecular docking and experimental investigation.

Manoochehri H, Farrokhnia M, Sheykhhasan M, Mahaki H, Tanzadehpanah H Heliyon. 2024; 10(14):e34300.

PMID: 39108872 PMC: 11301165. DOI: 10.1016/j.heliyon.2024.e34300.

The overexpression of cyclin D1 is a positive prognostic factor in advanced-stage breast carcinoma cases.

Aksoy A, Sevim M, Artas G North Clin Istanb. 2024; 10(6):726-733.

PMID: 38328730 PMC: 10846570. DOI: 10.14744/nci.2022.32657.

References

Ishii Y, Pirkmaier A, Alvarez J, Frank D, Keselman I, Logothetis D . Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model. J Natl Cancer Inst. 2006; 98(17):1238-47. DOI: 10.1093/jnci/djj334. View

Zheng J, Benbrook D, Yu H, Ding W . Clioquinol suppresses cyclin D1 gene expression through transcriptional and post-transcriptional mechanisms. Anticancer Res. 2011; 31(9):2739-47. View

Bilalovic N, Vranic S, Basic H, Tatarevic A, Selak I . Immunohistochemical evaluation of cyclin D1 in breast cancer. Croat Med J. 2005; 46(3):382-8. View

Yoshida T, Zhang Y, Rosado L, Chen J, Khan T, Moon S . Blockade of Rac1 activity induces G1 cell cycle arrest or apoptosis in breast cancer cells through downregulation of cyclin D1, survivin, and X-linked inhibitor of apoptosis protein. Mol Cancer Ther. 2010; 9(6):1657-68. DOI: 10.1158/1535-7163.MCT-09-0906. View

Zhang S, Caamano J, Cooper F, Guo X, Klein-Szanto A . Immunohistochemistry of cyclin D1 in human breast cancer. Am J Clin Pathol. 1994; 102(5):695-8. DOI: 10.1093/ajcp/102.5.695. View

Lee A, Park W, Yim H, Lee M, Park G, Lee K . Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast. Jpn J Clin Oncol. 2007; 37(9):708-14. DOI: 10.1093/jjco/hym082. View

Reis-Filho J, Savage K, Lambros M, James M, Steele D, Jones R . Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol. 2006; 19(7):999-1009. DOI: 10.1038/modpathol.3800621. View

BLOOM H, Richardson W . Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957; 11(3):359-77. PMC: 2073885. DOI: 10.1038/bjc.1957.43. View

Arnold A, Papanikolaou A . Cyclin D1 in breast cancer pathogenesis. J Clin Oncol. 2005; 23(18):4215-24. DOI: 10.1200/JCO.2005.05.064. View

10.

Eeckhoute J, Carroll J, Geistlinger T, Torres-Arzayus M, Brown M . A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. Genes Dev. 2006; 20(18):2513-26. PMC: 1578675. DOI: 10.1101/gad.1446006. View

11.

Zhuang Y, Miskimins W . Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal. 2008; 3:18. PMC: 2613390. DOI: 10.1186/1750-2187-3-18. View

12.

Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C . Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res. 1994; 54(7):1812-7. View

13.

Alao J . The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer. 2007; 6:24. PMC: 1851974. DOI: 10.1186/1476-4598-6-24. View

14.

Naidu R, Abdul Wahab N, Yadav M, Kannan Kutty M . Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters. Oncol Rep. 2002; 9(2):409-16. View

15.

Yang X, Sherman M, Rimm D, Lissowska J, Brinton L, Peplonska B . Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev. 2007; 16(3):439-43. DOI: 10.1158/1055-9965.EPI-06-0806. View

16.

Brunelli M, Manfrin E, Martignoni G, Bersani S, Remo A, Reghellin D . HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy. Am J Clin Pathol. 2008; 129(6):907-11. DOI: 10.1309/MD79CDXN1D01E862. View

17.

Tobin N, Sims A, Lundgren K, Lehn S, Landberg G . Cyclin D1, Id1 and EMT in breast cancer. BMC Cancer. 2011; 11:417. PMC: 3192789. DOI: 10.1186/1471-2407-11-417. View

18.

Sutherland R, Musgrove E . Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res. 2002; 4(1):14-7. PMC: 154565. DOI: 10.1186/bcr411. View

19.

Jiang Q, Zhang H, Zhang P . ShRNA-mediated gene silencing of MTA1 influenced on protein expression of ER alpha, MMP-9, CyclinD1 and invasiveness, proliferation in breast cancer cell lines MDA-MB-231 and MCF-7 in vitro. J Exp Clin Cancer Res. 2011; 30:60. PMC: 3113748. DOI: 10.1186/1756-9966-30-60. View